ストックスクリーナーアプリを入手
36.50
4.86%
1.7044
前日終値:
$34.80
開ける：
$35.76
24時間の取引高:
3.45M
Relative Volume:
2.88
時価総額：
$3.84B
収益：
$628.56M
当期純損益:
$141.82M
株価収益率:
28.97
EPS:
1.26
ネットキャッシュフロー:
$142.60M
1週間 パフォーマンス:
-55.85%
1か月 パフォーマンス:
-54.82%
6か月 パフォーマンス:
-48.85%
1年 パフォーマンス:
-26.98%
1日の値動き範囲:
$35.12
$38.44
1週間の範囲:
$32.99
$82.98
52週間の値動き範囲:
$32.99
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
名前
Corcept Therapeutics Inc
セクター
電話
650.688.8803
住所
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
36.51 | 3.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.03 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.91 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.88 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.39 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.91 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | UBS | Neutral |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-06 | アップグレード | Truist | Hold → Buy |
| 2023-04-11 | 開始されました | SVB Securities | Market Perform |
| 2023-04-04 | 開始されました | Piper Sandler | Overweight |
| 2023-02-15 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-01 | ダウングレード | Truist | Buy → Hold |
| 2022-07-27 | アップグレード | Jefferies | Hold → Buy |
| 2022-06-27 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-02 | 開始されました | Canaccord Genuity | Buy |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2020-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-09-24 | 開始されました | Jefferies | Buy |
| 2019-09-06 | 開始されました | H.C. Wainwright | Buy |
| 2019-02-04 | ダウングレード | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 繰り返されました | Stifel | Hold |
| 2018-05-31 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-09 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 開始されました | Stifel | Buy |
| 2017-02-02 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-04-21 | 開始されました | FBR Capital | Outperform |
| 2014-01-13 | ダウングレード | Stifel | Buy → Hold |
| 2013-08-09 | ダウングレード | Janney | Buy → Neutral |
| 2013-08-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2010-01-06 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | アップグレード | Punk, Ziegel & Co | Mkt Perform → Accumulate |
すべてを表示
Corcept Therapeutics Inc (CORT) 最新ニュース
FDA rejects relacorilant for Cushing’s-related high blood pressure - Cushing's Disease News
Corcept Therapeutics (NASDAQ:CORT) Trading Up 9.7%Here's What Happened - MarketBeat
The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away - Barchart.com
Implied Volatility Surging for Corcept Stock Options - TradingView — Track All Markets
Canaccord Genuity Adjusts Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Mind Medicine (MNMD) - The Globe and Mail
Ulta Beauty To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Given New $99.00 Price Target at Canaccord Genuity Group - MarketBeat
Corcept Therapeutics stock price target lowered to $90 at H.C. Wainwright - Investing.com UK
Corcept Therapeutics stock price target cut by Canaccord on FDA setback - Investing.com Canada
Corcept Therapeutics (CORT) Faces FDA Setback, But Growth Potent - GuruFocus
HC Wainwright & Co. Lowers Price Target for Corcept Therapeutics (CORT) | CORT Stock News - GuruFocus
US FDA declines to approve Corcept's drug for rare hormonal disorder - Reuters
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - The National Law Review
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT - ts2.tech
Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets - ts2.tech
A Risky Spot For Corcept Therapeutics (NASDAQ:CORT) - Seeking Alpha
What drives Corcept Therapeutics Incorporated stock priceTrading Psychology Tips & Build Wealth With Strategy - earlytimes.in
FDA says it needs additional evidence of effectiveness for Corcept relacorilant - Yahoo Finance
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio - TradingView — Track All Markets
The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56% - simplywall.st
Why We're Not Concerned Yet About Corcept Therapeutics Incorporated's (NASDAQ:CORT) 56% Share Price Plunge - 富途牛牛
Corcept Therapeutics stock tanks 50% after FDA relacorilant setback — what’s next for CORT - ts2.tech
Why Corcept Therapeutics plummeted by 50% today - MSN
Why Corcept Therapeutics Plummeted by 50% Today - The Globe and Mail
Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension - ts2.tech
Why Corcept Therapeutics Plummeted by 50% Today - The Motley Fool
Why Corcept (CORT) Shares Are Falling Today - Finviz
Why Corcept Therapeutics stock crashed today and what comes next? - CryptoRank
Corcept stumbles after Cushing's drug met with FDA rebuff - FirstWord Pharma
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations - NewMediaWire
Corcept Therapeutics price target lowered to $50 from $135 at Truist - TipRanks
Corcept Therapeutics Faces FDA Setback for Relacorilant Approval - TipRanks
Corcept Therapeutics Inc Receives FDA Complete Response Letter for Relacorilant - TradingView — Track All Markets
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next - ts2.tech
Stock Traders Buy Large Volume of Put Options on Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept - marketscreener.com
Truist Securities lowers Corcept Therapeutics stock price target on FDA concerns - Investing.com Nigeria
US FDA declines to approve Corcept’s drug for rare hormonal disorder - WTAQ
Corcept nosedives 48% after FDA rejected core drug - breakingthenews.net
Nasdaq Moves Lower; US Crude Oil Inventories Decline Sharply - Benzinga
Nvidia, Tesla, Nike, DJT, Hecla, Newmont, Corcept, Vanda, and More Market Movers - Barron's
Corcept Therapeutics (CORT) Sees Significant Decline in Stock Va - GuruFocus
Corcept Therapeutics Stock (CORT) Opinions on FDA Rejection of Relacorilant - Quiver Quantitative
Corcept Therapeutics Shares Drop 50% After FDA Rejects Drug - Barron's
Stocks making the biggest moves midday: Nike, Corcept Therapeutics, Taiwan Semiconductor & more - CNBC
Corcept looks to ovarian cancer as relacorilant gets CRL in Cushing - BioWorld MedTech
Corcept Therapeutics (NASDAQ:CORT) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Nvidia, Tesla, Hecla, Newmont, Nike, Vanda, Corcept, DJT, and More Market Movers - Barron's
Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30 - marketscreener.com
Wolfe Research downgrades Corcept Therapeutics stock rating to Underperform By Investing.com - Investing.com UK
Corcept Therapeutics Inc (CORT) 財務データ
収益
当期純利益
現金流量
EPS
Corcept Therapeutics Inc (CORT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| BELANOFF JOSEPH K | Chief Executive Officer |
Dec 24 '25 |
Option Exercise |
3.88 |
550,000 |
2,134,000 |
550,000 |
| Guyer William | Chief Development Officer |
Dec 02 '25 |
Option Exercise |
21.65 |
20,000 |
433,000 |
21,235 |
| Guyer William | Chief Development Officer |
Dec 02 '25 |
Sale |
80.08 |
20,000 |
1,601,526 |
1,235 |
| Maduck Sean | See Remarks |
Dec 01 '25 |
Option Exercise |
8.27 |
20,000 |
165,400 |
27,904 |
| Maduck Sean | See Remarks |
Dec 01 '25 |
Sale |
79.52 |
20,000 |
1,590,490 |
7,904 |
| Lyon Joseph Douglas | See Remarks |
Dec 01 '25 |
Option Exercise |
13.56 |
5,000 |
67,800 |
15,277 |
| Lyon Joseph Douglas | See Remarks |
Dec 01 '25 |
Sale |
79.53 |
5,000 |
397,632 |
10,277 |
| BELANOFF JOSEPH K | Chief Executive Officer |
Dec 01 '25 |
Sale |
79.77 |
40,000 |
3,190,796 |
2,701,370 |
0.52%
2.00%
大文字化:
|
ボリューム (24 時間):